InvestorsHub Logo
Followers 138
Posts 22888
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Sunday, 12/21/2014 12:38:35 AM

Sunday, December 21, 2014 12:38:35 AM

Post# of 2206

Positive efficacy results from the TT-034 Phase I/IIa clinical study, and to a lesser degree Calimmune’s Cal-1 programme, would help validate the ddRNAi platform and should be a major value inflexion point.



http://www.edisoninvestmentresearch.com/serve_pdf.php?d=researchreports&f=BenitecBiopharma_QV_240214.pdf&first_name=&last_name=&company=&email=

Good luck and GOD bless and Merry CHRISTmas and Happy Hanukkah.

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News